Stereospecific pharmacokinetics and toxicodynamics of ketorolac after oral administration of the racemate and optically pure enantiomers to the rat

Chirality

Volumn 11, Issue 3, 1999, Pages 201-205

  Jamali, F ^c   Lovlin, R ^d   Corrigan, B W ^d   Davies, N M ^d   Aberg, G ^a,b  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b Bridge Pharma Inc   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

KETOROLAC;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHIRALITY; CONTROLLED STUDY; DRUG PENETRATION; ENANTIOMER; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RACEMIC MIXTURE; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CHELATING AGENTS; CHROMIUM RADIOISOTOPES; EDETIC ACID; KETOROLAC; MALE; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; SUCROSE; TOLMETIN;

EID: 0033050775     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-636X(1999)11:3<201::AID-CHIR5>3.0.CO;2-Z     Document Type: Article

References (34)

1. Rainsford KD. Animal models for the assay of gastrointestinal toxicity of antiinflammatory drugs. In: Greenwald RA, Diamond HS, editors. Handbook of animal models for rheumatic diseases. Boca Raton FL: 8A CRC Press, 1988. p 188-206.
2. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? J Rheumatol 1991;18:7-11.
3. Wiedrick JED, Friesen EG, Garton AM, Otten NHH. Upper gastrointestinal bleeding associated with oral ketorolac therapy. 1. Ann Pharmacother 1994;28:1109.
4. Traversa G, Walker A, Ippolito FM, Caffan B, Capurso L, Dezi A, Koch M, Maggini M, Alegiani S, Raschetti R. Gastroduodenal toxicity of different NSAIDs: a case control study in the province of Rome. Epidemiology 1995;6:49-54.
5. Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wilholm BE, Alfredsson L, Koff RS, Shapiro S. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993;53:485-494.
6. Asbakken L, Larsen S, Osnes M. Visual analogue scale for endoscopic evaluation of non-steroidal anti-inflammatory drug induced mucosal damage in the stomach and duodenum. Scand Gastroenterol 1990;25: 443-448.
7. Bjarnson I, Williams P, Smethurst P, Peters TJ, Levi AJ. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986;27:1292-1297.
8. Meddings JB, Sutherland LR, Byles NI, Wallace JL. Sucrose: a novel permeability marker for gastroduodenal disease (see comments). Gastroenterology 1993;104:1619-1626.
9. Sutherland, LR, Verhoef M, Wallace JL, Van Rosendaal G, Crutcher RM. A simple, non-invasive marker of gastric damage: sucrose permeability. Lancet 1994;343:998-1000.
10. Davies NM, Corrigan BW, Jamali F. Sucrose urinary excretion in the rat using a simple assay: a model of gastroduodenal permeability. Pharm 1995;12:1733-1736.
11. Davies NM, Wright M, Jamali F. Anti-inflammatory drug-induced intestinal permeability: the rat is a suitable model. Pharm Res 1994;11: 1652-1659.
12. Ford J, Martin SW, Houston JB. Assessment of intestinal permeability changes induced by nonsteroidal anti-inflammatory drugs in the rat. J Pharmacol Toxicol Methods 1995;34:9-16.
13. Hutt AJ, Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids - a novel route with pharmacological consequences. J Pharm Pharmacol 1983;35:693-704.
14. Jamali, F. Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs. Eur J Drug Metab Pharmacokinet 1988;13:1-9.
15. Vakily M, Corrigan BW, Jamali F. The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. Pharm Res 1995;12:1652-1657.
16. Brandl M, conley D, Johnson D. Racemization of Ketorolac in aqueous solution. J Pharm Sci 1996;84:1045-1049.
17. Berry BW, Jamali F. Enantiomeric interaction of flurbiprofen in the rat. J Pharm Sci 1989;78:632-634.
18. Murphy PJ, Nickander RC, Bellamy GM, Kurtz WL. Effect of 1-propoxyphene on plasma levels and analgesic activity of d-propoxyphene in the rat. J Pharmacol Exp Ther 1976;199:415-422.
19. Hayball PJ, Tamblyn JG, Holden Y, Wrobel J. Stereoselective analysis of ketorolac in human plasma by high performance liquid chromatography. Chirality 1993;5:31-35.
20. Hayball PJ, Holman JW, Nation RL, Massay-Westrop RA, Hamon DPG. marked enantioselective protein binding in humans of ketorolac invitro: elucidation of enantiomer unbound fractions following facile synthesis and direct chiral HPLC resolution of tritium labelled ketorolac. Chirality 1994;6:642-648.
21. Hayball PJ, Wrobel J, Tamblyn JG, Nation RL. The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. Br J Clin Pharmacol 1994;37:75-78.
22. Mroszcak E, Combs D, Tsina I, Tam Y, Massey I, Chaplin M, Yee J. Pharmacokinetics of (-)S and R(+) enantiomers of ketorolac (K) in humans following administration of racemic ketorolac tromethamine (KT). Clin Pharmacol Ther 1991;49:126.
23. Jallad N, Garg D, Martinez J, Mroszcak E, Weidler D. Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. J Clin Pharmacol 1990;30:76-81.
24. Jamali F, Mehvar R, Lemko C, Eradiri O. Application of a stereospecific high-performance liquid chromatography assay to a pharmacokinetic study of etodolac enantiomers in humans. J Pharm Sci 1988;77:963-966.
25. Jamali F, Mehvar R, Pasutto FM. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J Pharm Sci 1989;78:695-715.
26. Chen CS, Shieh WR, Lu PH, Harriman S, Chen CY. Metabolic stereoisomeric inversion of ibuprofen in mammals. Biochim Biophys Acta 1991;1078:411-417.
27. Tanaka Y, Shimomura Y, Hirota T, Nozaki A, Ebata M, Takasaki W, Shigehara E, Hayashi R, Caldwell J. Formation of glycine conjugate and (-)-(R)-enantiomer from (+)-(S)-2-phenylpropionic acid suggesting the formation of the CoA thioester intermediate of (+)-(S)-enantiomer in dogs. Chirality 1992;4:342-348.
28. Jamali F, Lovlin R, Aberg G. Bi-directional chiral inversion of ketoprofen in CD-1 mice. Chirality 1997;9:29-31.
29. Fournel S, Caldwell J. The metabolic chiral inversion of 2-phenylpropionic acid in rat, mouse and rabbit. Biochem Pharmacol 1986;35: 4153-4159.
30. Choi VM, Coates JE, Chooi J, Thomson AB, Russell AS. Small bowel permeability - a variable effect of NSAIDS. Clin Invest Med 1995;18: 357-361.
31. Davies NM, Jamali F, Skeith KJ. Nonsteroidal antiinflammatory drug-induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis. Arthritis Rheum 1996;39:321-324.
32. Davies NM, Wright MR, Russell AS, Jamali F. Effect of the enantiomers of flurbiprofen, ibuprofen, and ketoprofen on intestinal permeability. J Pharm Sci 1996;85:1170-1173.
33. McCracken JD, Wechter WJ, Quiggle D, Liu YJ, Chase R, Mineyama Y. R-isomer of flurbiprofen decreases colonic proliferation without causing significant small bowel ulceration. J Clin Pharmacol 1996;36: 489a.
34. Wechter WJ, Bigornia AE, Murray ED, Jr, Levine BH, Young JW. Rac-flurbiprofen is more ulcerogenic than its (S)-enantiomer. Chirality 1995;5:492-494.